According to new study, Patients with atopic dermatitis (AD) also known as eczema often face a tough, uphill battle for treatment. Symptoms include severe itching, scaly rashes, extreme dry skin and inflammation. Those who suffer from AD spend sleepless, itchy nights fearing they have nowhere to turn and their symptoms may never resolve. This creates therapeutic challenges for clinicians treating AD. This study was published in Annals of Allergy, Asthma and Immunology.

Treatment for AD has altered a lot in the last few years. New treatments with new drugs were available and offer liberation. Mark Boguniewicz said, "The Atopic Dermatitis Yardstick was written by AD experts who are allergists and dermatologists because we want physicians who see patients with AD on a regular basis to know there are effective treatment options available.”

"In the yardstick, we cover the challenges and barriers to treatment success. We offer definitions of disease severity, review treatment failures, address treatment in a step wise fashion and cover the emerging science and implications for new therapies." Itching is the hallmark of AD, and the cycle of itching and scratching makes the condition worse because it causes damage to the skin and often creates secondary infections, which can be serious.

AD patients are at increased risk, not only for skin infections, but, according to a recent study, also for multi-organ and systemic infections. Patients with AD can present with a range of disease severity, from mild intermittent disease to severe difficult-to-control disease. The last few years have seen the introduction of targeted therapies, also known as "precision medicine". Two new medications have recently been approved for AD.

The first, crisaborole, is an ointment that reduces itching, redness and swelling of the skin. It is the first anti-inflammatory medication to be approved for the treatment of mild to moderate AD in more than 15 years.  It is approved for patients 2 years of age or older. Dupilumab, the second new medication, is a biologic therapy given by injection for patients 18 years or older with moderate to severe AD who haven't responded to, or can't use topical medications.

Dr. Fonacier said, "There are effective medications available that help relieve AD symptoms and now can also target some of the underlying mechanisms of the disease." "People with AD have been frustrated by the limitations of existing treatments. We're very excited by the new medications which were developed based on better understanding of atopic dermatitis.

As in further studies, they expect additional therapies for an approval. Allergists have the right training and expertise to diagnose AD, and to offer relief with the right treatments. Its glad that they could provide treatments to our arsenal of weapons to combat the symptoms of AD.